Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc.（LRMR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · LRMR · 截至 2026年6月9日
活动摘要
买入笔数
10
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Larimar Therapeutics, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
LRMR 季度内部人买卖趋势
LRMR 内幕交易卖出 · LRMR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · LRMR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
LRMR 高管卖出股份 · LRMR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 27, 2026 | Flynn James E Director | Purchase | 1,084,012 | $5.42M⚡ | Form 4 |
| Feb 27, 2026 | Flynn James E Director | Purchase | 1,084,010 | $5.42M⚡ | Form 4 |
| Feb 27, 2026 | Flynn James E Director | Purchase | 831,978 | $4.16M⚡ | Form 4 |
| Feb 27, 2026 | Flynn James E Director | Purchase | 2,000,000 | $10.00M⚡ | Form 4 |
| Feb 27, 2026 | Hamilton Thomas Edward Director | Purchase | 100,000 | $500K | Form 4 |
| Feb 27, 2026 | THOMAS FRANK E Director | Purchase | 5,000 | $25K | Form 4 |
| Feb 27, 2026 | SHERMAN JEFFREY W Director | Purchase | 5,000 | $25K | Form 4 |
| Jan 26, 2026 | Shankar Gopi Chief Development Officer | Award | 25,637 | — | Form 4 |
| Jan 26, 2026 | Clayton Russell Chief Medical Officer | Award | 25,637 | — | Form 4 |
| Jan 26, 2026 | BEN-MAIMON CAROLE President and CEO · Director | Award | 100,100 | — | Form 4 |
| Jan 26, 2026 | Celano Michael CFO | Award | 37,604 | — | Form 4 |
| Jul 31, 2025 | Flynn James E Director | Purchase | 3,387,539 | $10.84M⚡ | Form 4 |
| Jul 31, 2025 | Flynn James E Director | Purchase | 3,387,529 | $10.84M⚡ | Form 4 |
| Jul 31, 2025 | Flynn James E Director | Purchase | 2,599,932 | $8.32M⚡ | Form 4 |
| Jan 22, 2025 | Shankar Gopi Chief Development Officer | Award | 23,306 | — | Form 4 |
| Jan 22, 2025 | Clayton Russell Chief Medical Officer | Award | 23,306 | — | Form 4 |
| Jan 22, 2025 | BEN-MAIMON CAROLE President and CEO · Director | Award | 91,000 | — | Form 4 |
| Jan 22, 2025 | Celano Michael CFO | Award | 34,185 | — | Form 4 |
| Feb 16, 2024 | Hamilton Thomas Edward Director | Purchase | 57,208 | $500K | Form 4 |
| Feb 16, 2024 | Flynn James E Director | Purchase | 1,430,206 | $12.50M⚡ | Form 4 |
| Feb 16, 2024 | Flynn James E Director | Purchase | 1,430,206 | $12.50M⚡ | Form 4 |
| Feb 16, 2024 | Flynn James E Director | Purchase | 1,430,205 | $12.50M⚡ | Form 4 |
| Feb 14, 2024 | THOMAS FRANK E Director | Purchase | 2,000 | $22K | Form 4 |
| Jan 17, 2024 | Shankar Gopi Chief Development Officer | Award | 22,500 | — | Form 4 |
| Jan 17, 2024 | Celano Michael CFO | Award | 31,250 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 LRMR 内幕交易
LRMR 内幕交易
Larimar Therapeutics, Inc.（LRMR）内幕交易数据来源于公司内部人（包括Flynn James E (Director), Hamilton Thomas Edward (Director), THOMAS FRANK E (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。LRMR内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Larimar Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
LRMR 内幕交易 · 5个问题Larimar Therapeutics, Inc.（LRMR）的内部人包括高管和董事，如Flynn James E (Director), Hamilton Thomas Edward (Director), THOMAS FRANK E (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026